fda decision on tirzepatide Eli Lilly's gained approval in December 2024 for treating moderate-to-severe obstructive sleep apnea in adults with obesity, after Phase III trials showed a 20% average weight loss and a roughly Eli Lilly seeks FDA approval

Perimenopause-specific considerations include timing: some women find injections easier to tolerate if given during lower-stress times of their cycle, though this is not medically necessary

The current listing also offers a 10mg option, but the reviewed COA should not be stretched to cover that size without matching records

Sensations of anxiety or unease

Staying at a lower dose for longer before moving up may not be a bad idea and is completely normal

At InjectCos BriteBody weight loss program, monthly check-ins allow providers to adjust dosing based on where you are in your weight loss journey, including transitioning to a maintenance phase at the right time

Supplementary material The Supplementary Material for this article can be found online at: References 1 ApiA.BelsitoD.BotelhoD.BruzEM.BurtonG.CancellieriM.et al